Literature DB >> 19839936

The endocannabinoid system and the treatment of mood and anxiety disorders.

Matthew N Hill1, Boris B Gorzalka.   

Abstract

The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioral responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioral responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19839936     DOI: 10.2174/187152709789824624

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  58 in total

1.  Cannabinoid modulation of subgenual anterior cingulate cortex activation during experience of negative affect.

Authors:  Christine A Rabinak; Chandra Sekhar Sripada; Mike Angstadt; Harriet de Wit; K Luan Phan
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

2.  Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.

Authors:  Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

3.  A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers.

Authors:  Elias Dakwar; Edward V Nunes; Adam Bisaga; Kenneth C Carpenter; John P Mariani; Maria A Sullivan; Wilfrid N Raby; Frances R Levin
Journal:  Am J Addict       Date:  2011-07-11

4.  The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Authors:  Mano Aliczki; Istvan Barna; Ibolya Till; Maria Baranyi; Beata Sperlagh; Steven R Goldberg; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2016-01-26       Impact factor: 4.530

5.  Pregabalin influences insula and amygdala activation during anticipation of emotional images.

Authors:  Robin L Aupperle; Lakshmi Ravindran; Dharol Tankersley; Taru Flagan; Nathan R Stein; Alan N Simmons; Murray B Stein; Martin P Paulus
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

Review 6.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

7.  Behavioral responses to acute and sub-chronic administration of the synthetic cannabinoid JWH-018 in adult mice prenatally exposed to corticosterone.

Authors:  Simone Macrì; Lara Lanuzza; Gustavo Merola; Chiara Ceci; Stefano Gentili; Antonella Valli; Teodora Macchia; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-01-08       Impact factor: 3.911

Review 8.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

9.  Interactions Between Anandamide and Corticotropin-Releasing Factor Signaling Modulate Human Amygdala Function and Risk for Anxiety Disorders: An Imaging Genetics Strategy for Modeling Molecular Interactions.

Authors:  Catherine H Demers; Emily Drabant Conley; Ryan Bogdan; Ahmad R Hariri
Journal:  Biol Psychiatry       Date:  2016-01-05       Impact factor: 13.382

10.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.